Menopause is a normal part of aging when menstrual periods in women stop permanently, meaning the continuous absence of menstrual periods for 12 months. Menopause does not happen instantly but as a gradual process of changes called perimenopause which is a transition to menopause, when periods become rare and irregular but a woman can still conceive.
During perimenopause, fertility treatments like IVF can help a woman achieve pregnancy, but due to poor quality eggs as a result of the woman’s age, there are difficulties in producing healthy embryos. After menopause, the only way a woman to become pregnant was with the use of donor eggs or embryo adoption.
Until now, there has not been an option for effective, non-hazardous treatment that can achieve the restoration of the ovarian function in menopausal women.
SEGOVA is the group of biotechnological procedures using autologous, natural, safe sources of patient’s biological factors that can help retrieve the lost ovarian function and boost hormone production in hormone-secreting cells.
It provides the rise of estrogen levels and decrease of FSH, restoring the endocrine balance, relieving the symptoms of menopause, delaying the onset of associated diseases and improving the quality of life.
SEGOVA ovarian rejuvenation is a program designed to help boost the ovaries to restore proper folliculogenesis and contribute with the sources of signaling molecules in the ovaries to achieve an adequate environment for oocyte development.
SEGOVA is a group of methods based on biological therapy using autologous, natural, safe sources that can help retrieve the impaired ovarian function and balance hormone production in hormone-secreting cells. It provides benefit by restoring the endocrine homeostasis and boosting the local ovarian environment to help obtain good quality oocytes and successful reproductive outcomes.
The sample of 93 patients aged 31 to 60 years (average age of 46,64 years) with diagnosis of infertility have completed SEGOVA ovarian rejuvenation and participated in a two year monitoring.
Percentage of women with presence of a follicle out of total number of patients.
Percentage out of total number of follicle positive patients (24,73% out of total number of patients ).
Percentage out of total number of oocyte positive patients (20,43% out of total number of patients).
Percentage out of total number of patients who had embryos (12,9% out of total number of patients) 25 embryos vitrified 36 embryos transferred.
Our doctors are available for a free no obligation consultation every day.
Professor Aleksandar Ljubić (pictured), MD PhD is the President of Forever Young Holding – international biotech holding dedicated to use and development of cutting edge biotechnology products and services with the aim to increase overall health, human longevity and quality of life.
He is a pioneer in invasive ultrasound guided fetal procedures, direct maturation of fetal lungs, inventor of method of prenatal hearing screening (PHS) (Sovilj-Ljubic), non-surgical fibroids treatment, and advanced NOTES laparoscopic procedures.
His main research areas are biotechnology in reproductive and perinatal medicine, assisted reproduction and minimally invasive reproductive surgery.
He has authored autologous in vitro genetic ovarian activation and is the author of the SEGOVA ovarian rejuvenation method. He was awarded a number of national and international recognitions and awards: First investigator Award (USA), Belgrade Science Award (Serbia), Sir William Lilley Award (WAPM).
Professor Ljubić was editor and co-editor in several scientific magazines, was President of the World Congress of perinatal medicine in 2017. He was the principal investigator in 11 scientific projects, published almost 500 publications – In peer-reviewed magazines – 62, with Citation index – 400.
Prof. Dr. Ljubić is a full professor at the DIU and visiting professor at Weill Cornell Medical School, USA. He was educated at Belgrade University with postgraduate education in the USA, Japan and Greece. For more than 25 years, he worked at the Medical School, University of Belgrade, Clinic for Obstetrics & Gynecology and Clinical Center of Serbia as a professor and a Head of Clinic.
Professor Ljubić is also a Deputy Secretary-General of World Association for Perinatal Medicine, Board member of the Fetus as a patient society and Associate member of International Academy of Perinatal Medicine.
Email Us
Quick Links